24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Gilead Sciences
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:56
Mobileye first quarter revenue falls by almost 50% as clients cut back on spending to clear excess stock
14:00
Melio names Boaz BenDavid as its first Chief Financial Officer
13:28
Check Point registers higher than expected Q1 profit helped by growth of AI-powered security platform
09:26
Microsoft explains how Generative AI impacts IP law and compliance
More stories
Buzz
Most popular
Daily
Weekly
1
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
2
Nvidia continues Israel shopping spree with acquisition of Deci
3
Nvidia announces $700 million acquisition of Run:ai
4
Nvidia on verge of completing $700 million acquisition of Run:ai
5
Nagomi Security raises $23 million Series A for proactive defense platform
More news
Gilead Sciences
5 stories about Gilead Sciences
Investments are flowing into synthetic biology - the red-hot field that will change the world
28.07.21
|
Sophie Shulman
Synthetic biology seemed like science fiction until the arrival of the coronavirus vaccines. But now the money has begun to flow and companies are revealing remarkable inventions: from bacteria that will attack tumors to shoes made of cobwebs
ForeBio is on its way to Nasdaq at a $500 million valuation
01.03.21
|
Tzally Greenberg
The company aims to raise $100 million in an April IPO, while Pontifax and OrbiMed who previously invested $21 million for a 12.5% stake in ForeBio’s shares are expected to make a $120 million profit
Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company
10.12.17
|
Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
Kite Pharma’s Cancer Drug Gets Regulatory Nod
19.10.17
|
Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
Kite Pharma Sale Triggers Scientist Quarrel
02.10.17
|
Zohar Shahar Levy
Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur
Please ensure Javascript is enabled for purposes of
website accessibility